CN105902708A - Medical formula capable of preventing and treating myopia - Google Patents

Medical formula capable of preventing and treating myopia Download PDF

Info

Publication number
CN105902708A
CN105902708A CN201610289573.XA CN201610289573A CN105902708A CN 105902708 A CN105902708 A CN 105902708A CN 201610289573 A CN201610289573 A CN 201610289573A CN 105902708 A CN105902708 A CN 105902708A
Authority
CN
China
Prior art keywords
parts
myopia
vitamin
treatment
lutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610289573.XA
Other languages
Chinese (zh)
Inventor
杨海峰
杨树立
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN201610289573.XA priority Critical patent/CN105902708A/en
Publication of CN105902708A publication Critical patent/CN105902708A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/482—Cassia, e.g. golden shower tree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The invention relates to a medical formula capable of preventing and treating myopia. The medical formula comprises lutein, zeaxanthin, Semen Cassiae, carotene, Stigma Croci Sativi, cinnamon oil, tannin, pectin, vitamin C and vitamin E. The medical formula capable of preventing and treating the myopia has the advantages that the medical formula is capable of decreasing myopic degree and astigmatic degree and treating pseudomyopia and relieving visual fatigue effectively.

Description

A kind of prevention, the medical formulation for the treatment of myopia
Technical field
The present invention relates to a kind of pharmaceutical formulation, be specifically related to a kind of prevention, the medicine for the treatment of myopia Formula.
Background technology
Myopia is ametropic one.It is that object at a distance can not converge at retina, and Forming focus before retina, thus result in visual deformation, the object causing a distant place is smudgy.
The ascendant trend of adolescent myopia patient populations is fairly obvious in recent years.China has more than 4 Hundred million A nearsighted persons.
Major part myopia occurs teenager, deepens year by year at the development growth stage number of degrees, arrives Do not develop or slower development after reaching maturity.Its myopia degree rarely exceeds 6D, eyeground Not occurring degeneration to change, eyesight can be with mirror wildcarding correcting, referred to as simple myopia.Another kind of near Depending on occurring relatively early (can occur between 5～10 years old), and making much progress, 25 years old with follow-up Supervention exhibition, myopia degree, up to more than 15D, is often accompanied by Fundus oculi changes, and eyesight is difficult to correct, It is referred to as degenerative myopia.
The mode DeGrain of drug therapy myopia in recent years.
Summary of the invention
It is an object of the invention to for deficiency of the prior art, it is provided that a kind of drug effect is the most pre- Anti-, the medical formulation for the treatment of myopia.
For achieving the above object, the invention discloses following technical scheme:
A kind of prevention, the medical formulation for the treatment of myopia, including following composition in terms of mass parts, Mixing aft-loaded airfoil becomes powder to be prepared from:
Lutein 10～18 parts
Beautiful xanthin 10～15 parts
Cassia seed 10～15 parts
Carrotene 10～15 parts
Safflower 10～15 parts
Cinnamon oil 10～15 parts
Tannic acid 10～16 parts
Pectin 10～15 parts
Vitamin C 6～15 parts
Vitamin E 8～15 parts.
As a kind of preferred version, including following composition in terms of mass parts, mixing aft-loaded airfoil becomes Powder is prepared from:
15 parts of lutein
Beautiful xanthin 10 parts
Cassia seed 15 parts
Carrotene 15 parts
Safflower 10 parts
Cinnamon oil 10 parts
15 parts of tannic acid
Pectin 10 parts
Vitamin C 10 parts
Vitamin E 10 parts.
As a kind of preferred version, including following composition in terms of mass parts, mixing aft-loaded airfoil becomes Powder is prepared from:
10 parts of lutein
Beautiful xanthin 15 parts
Cassia seed 10 parts
Carrotene 10 parts
Safflower 15 parts
Cinnamon oil 10 parts
10 parts of tannic acid
Pectin 15 parts
Vitamin C 15 parts
Vitamin E 8 parts.
A kind of prevention disclosed by the invention, the medical formulation for the treatment of myopia, have following useful effect Really:
The medical formulation of the present invention can effectively reduce myopia degree and astigmatism degree, highly effective Ground treatment pseudo-myopia, alleviation visual fatigue.
Detailed description of the invention
Below in conjunction with embodiment, the invention will be further described.
A kind of prevention, the medical formulation for the treatment of myopia, including following composition in terms of mass parts, Mixing aft-loaded airfoil becomes powder to be prepared from:
Lutein 10～18 parts
Beautiful xanthin 10～15 parts
Cassia seed 10～15 parts
Carrotene 10～15 parts
Safflower 10～15 parts
Cinnamon oil 10～15 parts
Tannic acid 10～16 parts
Pectin 10～15 parts
Vitamin C 6～15 parts
Vitamin E 8～15 parts.
Embodiment 1
A kind of prevention, the medical formulation for the treatment of myopia, including following composition in terms of mass parts, Mixing aft-loaded airfoil becomes powder to be prepared from:
15 parts of lutein
Beautiful xanthin 10 parts
Cassia seed 15 parts
Carrotene 15 parts
Safflower 10 parts
Cinnamon oil 10 parts
15 parts of tannic acid
Pectin 10 parts
Vitamin C 10 parts
Vitamin E 10 parts.
Embodiment 2
A kind of prevention, the medical formulation for the treatment of myopia, including following composition in terms of mass parts, Mixing aft-loaded airfoil becomes powder to be prepared from:
10 parts of lutein
Beautiful xanthin 15 parts
Cassia seed 10 parts
Carrotene 10 parts
Safflower 15 parts
Cinnamon oil 10 parts
10 parts of tannic acid
Pectin 15 parts
Vitamin C 15 parts
Vitamin E 8 parts.
Inventive formulation is externally applied drug, can be placed in eyeshade by medicine in use, apply at eye Portion, medicine acts directly on eye, makes efficacy of a drug fast onset effect.
Myopia and astigmatism degree are used for evaluating tested 21 days, 45 days, the eyesight status of 90 days, Record rafractive test result (numerical value is the highest, represents that eyesight status is the poorest).
Screen 50 tests object, the wherein male sex 25, women 25 (age 6-18 year).
In the case of not using the medical formulation of the present invention, these 50 test objects are surveyed Examination, after using embodiments of the invention continuously 90 days, tests, concrete correction data again It is shown in Table one:
Table one: Experimental comparison's data
As shown in Table 1, the medical formulation of the present invention can reduce myopia degree and astigmatism degree, Effectively treat pseudo-myopia and control myopia degree growth.
The above is only the preferred embodiment of the present invention, is not intended to limit；It should be pointed out that, Although the present invention being described in detail with reference to the various embodiments described above, the ordinary skill of this area Personnel should be appreciated that the technical scheme described in the various embodiments described above still can be repaiied by it Change, or the most some or all of technical characteristic is carried out equivalent；And these are revised and replace Change, do not make the essence of corresponding technical scheme depart from the model of various embodiments of the present invention technical scheme Enclose.

Claims (3)

1. a prevention, the medical formulation for the treatment of myopia, it is characterised in that include following with matter The composition of amount part meter, mixing aft-loaded airfoil becomes powder to be prepared from:
Lutein 10～18 parts
Beautiful xanthin 10～15 parts
Cassia seed 10～15 parts
Carrotene 10～15 parts
Safflower 10～15 parts
Cinnamon oil 10～15 parts
Tannic acid 10～16 parts
Pectin 10～15 parts
Vitamin C 6～15 parts
Vitamin E 8～15 parts.
A kind of prevention the most according to claim 1, the medical formulation for the treatment of myopia, it is special Levying and be, including following composition in terms of mass parts, mixing aft-loaded airfoil becomes powder to be prepared from:
15 parts of lutein
Beautiful xanthin 10 parts
Cassia seed 15 parts
Carrotene 15 parts
Safflower 10 parts
Cinnamon oil 10 parts
15 parts of tannic acid
Pectin 10 parts
Vitamin C 10 parts
Vitamin E 10 parts.
A kind of prevention the most according to claim 1, the medical formulation for the treatment of myopia, it is special Levying and be, including following composition in terms of mass parts, mixing aft-loaded airfoil becomes powder to be prepared from:
10 parts of lutein
Beautiful xanthin 15 parts
Cassia seed 10 parts
Carrotene 10 parts
Safflower 15 parts
Cinnamon oil 10 parts
10 parts of tannic acid
Pectin 15 parts
Vitamin C 15 parts
Vitamin E 8 parts.
CN201610289573.XA 2016-04-28 2016-04-28 Medical formula capable of preventing and treating myopia Pending CN105902708A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610289573.XA CN105902708A (en) 2016-04-28 2016-04-28 Medical formula capable of preventing and treating myopia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610289573.XA CN105902708A (en) 2016-04-28 2016-04-28 Medical formula capable of preventing and treating myopia

Publications (1)

Publication Number Publication Date
CN105902708A true CN105902708A (en) 2016-08-31

Family

ID=56753365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610289573.XA Pending CN105902708A (en) 2016-04-28 2016-04-28 Medical formula capable of preventing and treating myopia

Country Status (1)

Country Link
CN (1) CN105902708A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103735733A (en) * 2013-12-30 2014-04-23 杭州海杭生物医药科技有限公司 Compound preparation containing lutein ester and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103735733A (en) * 2013-12-30 2014-04-23 杭州海杭生物医药科技有限公司 Compound preparation containing lutein ester and preparation method thereof

Similar Documents

Publication Publication Date Title
Mojzis et al. Visual outcomes of a new toric trifocal diffractive intraocular lens
Alio et al. Clinical outcomes after complete ring implantation in corneal ectasia using the femtosecond technology: a pilot study
Tejedor et al. Choosing the location of corneal incision based on preexisting astigmatism in phacoemulsification
Manche et al. Wavefront-guided laser in situ keratomileusis (LASIK) versus wavefront-guided photorefractive keratectomy (PRK): a prospective randomized eye-to-eye comparison (an American Ophthalmological Society thesis)
Trindade et al. New pinhole sulcus implant for the correction of irregular corneal astigmatism
Almalki et al. Causes of elevated intraocular pressure following implantation of phakic intraocular lenses for myopia
Lee et al. Dynamic vaulting changes in V4c versus V4 posterior chamber phakic lenses under differing lighting conditions
Jabbarvand et al. Continuous corneal intrastromal ring implantation for treatment of keratoconus in an Iranian population
Ernest et al. Minimizing surgically induced astigmatism at the time of cataract surgery using a square posterior limbal incision
Alfonso et al. Posterior chamber phakic intraocular lenses after penetrating keratoplasty
CN109803652A (en) Ophthalmic pharmaceutical compositions and its associated uses
Agarwal et al. Visual outcomes and higher order aberrations following LASIK on eyes with low myopia and astigmatism
Kohnen et al. Long-term safety follow-up of an anterior chamber angle-supported phakic intraocular lens
Charles et al. Comparison of 2 wavefront-guided excimer lasers for myopic laser in situ keratomileusis: one-year results
Mol et al. Toric intraocular lenses for correction of astigmatism in keratoconus and after corneal surgery
Cagil et al. Photorefractive keratectomy in treatment of refractive amblyopia in the adult population
Jun et al. Clinical outcomes of mechanical and transepithelial photorefractive keratectomy in low myopia with a large ablation zone
Schallhorn et al. Outcomes of wavefront-guided laser in situ keratomileusis using a new-generation Hartmann-Shack aberrometer in patients with high myopia
Poyales et al. Comparison of visual performance and patient satisfaction outcomes with two trifocal IOLs with similar optical design but different materials
Whitman et al. Through-focus performance with a corneal shape–changing inlay: one-year results
Lee et al. Comparison of patient outcomes after implantation of Visian toric implantable collamer lens and iris-fixated toric phakic intraocular lens
Bandeira et al. Transitional conic toric intraocular lens for the management of corneal astigmatism in cataract surgery
CN105902708A (en) Medical formula capable of preventing and treating myopia
Panos et al. Idiopathic macular epiretinal membrane surgery with simultaneous internal limiting membrane peeling. The experience of the Fribourg Eye Clinic
Horng et al. Improvement of presbyopia using a mixture of traditional chinese herbal medicines, including cassiae semen, wolfberry, and dendrobium huoshanense

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160831